Tranylcypromine-agomelatine

From Psychiatrienet
Revision as of 14:48, 5 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from tranylcypromine to agomelatine.[1] [2]

Nietinrijdenbord.png Stop tranylcypromine
  • Day 1: Decrease the original dose with about 25% every 3 days.
Eenrichtingbord.png Start agomelatine
  • Day 15: Start and increase the dose with about 25% of the target dose every 3 days or 50% per week.
Infobord.png More information
  • Tranylcypromine has to be phased out to avoid withdrawal symptoms.
  • Because tranylcypromine is a irrivesible MAO inhibitor, the activity of MAO enzymes will be normal again after two weeks.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.